-
Article
Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
Correction to: Leukemia (2014) 28, 675–679; doi:10.1038/ leu.2013.225; published online 16 August 2013 Since the publication of this article, the authors have identified an error contained within the ‘Cell sor...
-
Article
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an im...
-
Article
Anticorps anti-VEGF: un emploi universel?
Il y a 25 ans, la convergence de plusieurs stratégies de recherches indépendantes vers un petit nombre de gènes a permis de fonder le paradigme des oncogènes, les «gènes de cancer» dont les dé règlements pertu...
-
Article
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma
The potential benefit of rituximab as adjuvant to high-dose therapy (HDT) has been investigated in patients under 60 years with poor-risk (age-adjusted international prognostic index at 2–3) CD20+ diffuse larg...
-
Article
Prise en charge à domicile des neutropénies fébriles courtes après chimiothérapie: résultats et leçons d’une étude pilote menée sur deux ans dans un centre de lutte contre le cancer
L’étude a pour but de tester la faisabilité d’une prise en charge précoce à domicile des aplasies fébriles sans facteurs de mauvais pronostic. Sur 517 épisodes de neutropénies fébriles enregistrés entre 07/99 ...
-
Article
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)
The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 prot...
-
Article
Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials
Since 1987, the GELA has initiated multicenter prospective trials for aggressive non-Hodgkin's lymphomas (NHL). Lymphoblastic lymphomas (LBL) were included in those studies until 1997, and 92 LBL patients unde...
-
Article
Open AccessBaseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
A risk model for febrile neutropenia (FN) after conventional cytotoxic chemotherapy, based on early (day 5) lymphopenia and the dose of chemotherapy, has been described. A risk index based on parameters availa...
-
Article
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients
With the introduction of new drugs such as alpha-interferon (IFN) and purine analogs, the management of hairy cell leukemia (HCL) patients has changed. However, deoxycoformycin (DCF) produced higher complete r...
-
Chapter and Conference Paper
Long-Term Survival after Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia
Over the past decade, great progress has been made in the treatment of adult acute lymphoblastic leukemia (ALL). Improvements in the quality and availability of broad-spectrum antibacterial antibiotics, antifu...
-
Article
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study
Mantle cell lymphoma (MCL) is a distinct clinico-pathological entity with a poor prognosis. We have conducted a prospective study in patients with MCL to evaluate a therapeutic strategy in which CHOP polychemo...
-
Article
Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period
Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred...
-
Article
Open AccessIdentification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
1–5% of cancer patients treated with cytotoxic chemotherapy die within a month after the administration of chemotherapy. Risk factors for these early deaths (ED) are not well known. The purpose of this study w...
-
Article
Open AccessHodgkins disease
-
Chapter and Conference Paper
Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87
Treatment of adult acute lymphoblastic leukemia (ALL) remains unsatisfactory [1-4]. Different strategies such as allogenic, autologous transplantation or more intensive chemotherapy may improve the outcome. Th...
-
Article
Research controversies in management of oral mucositis
The management of mucositis is the subject of many controversies, and the optimal treatment is still not known. Several evaluation scoring systems have been described, but no one of these is appropriate to al...
-
Article
High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients
Between 1985 and 1996, 18 patients with diffuse centrocytic lymphoma (DCL), including nine patients with an established histological and phenotypic diagnosis of mantle cell lymphoma (MCL), received 19 courses ...
-
Article
Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients
Acute lymphoblastic leukemia (ALL) in the elderly is characterized by its poor prognosis. Forty patients with ALL, aged 55 years or older, and with good performance status (ECOG <3) were prospectively treated ...
-
Chapter
Peripheral Blood Stem Cells Mobilization with G-CSF (FILGRASTIM) Alone for Autologous Transplant in Myeloid and Lymphoid Malignancies
In order to determine whether granulocyte colony-stimulating factor (G-CSF) alone was capable of mobilizing peripheral blood stem cells (PBSC) in myeloid as well in lymphoid malignancies, G-CSF (filgrastim), 5...
-
Article
Sequentisl induction chemotherapy with vincristine, daunorubicin cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia
Sequential chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone doses was administered to 57 adult patients with acute lymphoblastic leukemia (ALL). Complete remission (CR) was achieve...
